Cytek Biosciences (CTKB)
(Real Time Quote from BATS)
$6.50 USD
+0.17 (2.69%)
Updated Jul 16, 2024 09:36 AM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTKB 6.50 +0.17(2.69%)
Will CTKB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTKB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTKB
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
CTKB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
Cytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?
Other News for CTKB
Cytek Biosciences management to meet virtually with Piper Sandler
Cytek Biosciences management to meet virtually with Piper Sandler
Cytek Biosciences Announces $50 Million Stock Repurchase Program
Cytek Biosciences to effect an up to $50M share repurchase program
Cytek Biosciences announces $50M stock repurchase program